Henry Ford Hospital Medical Journal
Volume 26

Number 2

Article 6

6-1978

Refractory Hypercalcemia in Sarcoidosis: Exacerbation by
thiazide diuretics, differentiation from primary
hyperparathyroidism, and possible role of prolactin
A. M. Parfitt

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Parfitt, A. M. (1978) "Refractory Hypercalcemia in Sarcoidosis: Exacerbation by thiazide diuretics,
differentiation from primary hyperparathyroidism, and possible role of prolactin," Henry Ford Hospital
Medical Journal : Vol. 26 : No. 2 , 27-34.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol26/iss2/6

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been
accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System
Scholarly Commons.

Henry Ford Hosp Med Journal
Vol 26, No 2, 1978

Refractory Hypercalcemia in Sarcoidosis: Exacerbation by thiazide
diuretics, differentiation from primary hyperparathyroidism, and
possible role of prolactin
A. M. Parfitt, M D '

Hypercalcemia
in a patient with sarcoidosis
was made
worse by a thiazide diuretic initially given to control
hypercalciuria alone. The hypercalcemia
was unusually
resistant
to corticosteroid
treatment during the summer even after the
thiazide diuretic had been discontinued.
Lack of response to
corticosteroid
together with decreased tubular
reabsorption
of phosphate and increased tubular reabsorption of calcium
suggested associated
primary
hyperparathyroidism,
but
PTH was undetectable
by immunoassay, and
nephrogenous
cyclic AMP excretion was zero. Amenorrhea,
galactorrhea
and hyperprolactinemia
were found to be due to a pituitary
tumor which was removed. The experience with this patient
suggests that: 1) exacerbation of hypercalcemia
by thiazides
does not discriminate
between its different causes; 2) finding
low values for plasma parathyroid
homone
(PTH) and
nephrogenous
cyclic
AMP is the most certain way of
excluding
primary
hyperparathyroidism
in patients
with
hypercalcemia
from other causes; 3) prolactin
excess, by
increasing the synthesis of 1,25
dihydroxycholecalciferol,
may have intensified the calcium metabolism
disorder.

H YPERCALCURIA leading to nephrolithiasis and hypercalcemia leading to nephrocalcinosis are well recognized
complications of sarcoidosis.^ In most instances, the disordered calcium metabolism is readily controlled by dietary
calcium restriction and corticosteroids,^ but occasionally
these measures are relatively ineffective. Such a case is the
subject of this paper.

Case Report
A white woman, born in 1943, was first seen at Henry Ford EHospital
in November, 1975 at the age of 33 for recurrent kidney stones
associated with sarcoidosis. In 1961, at age 18, a normal pregnancy
was followed by amenorrhea. She did not want more children and
the cause was not estabi ished, but thyroid medication was given for
good measure. In 1967, at age 24, a routine chest x-ray was
abnormal; tuberculosis was suspected, but not confirmed. The
pulmonary infiltration progressed, and three years later, in 1970, a
biopsy o f a lymph node in the neck showed sarcoidosis. Corticosteroids were given for six weeks with inconclusive results. Apart
from a skin rash on the legs, she remained well without further
treatment for the nextthreeyears. In June, 1973, however, the first
sign of disordered calcium metabolism abruptly appeared. This
was a severe attack of left-sided ureteric colic which required a
ureterolithotomy. Similar attacks of pain, but lasting only 12-24
hours and always on the left side, recurred every few months, in
March, 1975 a more severe attack occurred on the right side and
required litholopaxy via cystoscopy.
Two months later her family physician referred her to the Baylor
College of /vledicine in Houston, Two stones were found in the left
kidney and one in the right, all of which were removed surgically.
The stones were composed of a mixture of calcium oxalate and
calcium phosphate. The plasma calcium was normal at 9.2 m g / d l ,
but urinary calcium excretion was increased to 428 m g / 2 4 hours
on a regular diet, decreasing to 169 mgon a low calcium diet. Renal
function was normal with a plasma creatinine of 1.0 m g / d l and a
creatinine clearance of 101 ml/minute. The diagnosis of sarcoidosis was confirmed by positive biopsies of a skin lesion on the
leg and of a para-aortic lymph node. There was diffuse interstitial
infiltration in the lungs with a combined restrictive and obstructive
defect in ventilation. Concerning the amenorrhea, morning and
evening plasma Cortisol, insulin tolerance test, including growth
hormone and Cortisol response and plasma levels of luteinizing
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hormone, triodothyronine, thyroxine, and thyroid stimulating hormone were all normal. The exogenous thyroid was stopped, and
she was discharged on a thiazide diuretic, a low calcium diet, and a
low sodium diet, all given to lower urinary calcium excretion.
Potassium phosphate was given as additional treatment for the
kidney stones, but was discontinued after a few months and
replaced by a nonphosphate containing potassium supplement.
Although there were no further attacks of ureteric colic, urinary
tract infections resumed and serial x-rays showed regrowth ofthe
stones.

function and inadequate control of stone formation, no improvements could be made in her treatment.
However, in April 1976, hypercalcemia was noted forthe first time,
the plasma calcium having risen to 11.6 mg/100 ml and the 24hour urinary calcium excretion to 306 mg. The dietary intake of
calcium, determined by accurate record of food consumption fora
week, was only 330 mg. The plasma parathyroid hormone (PTH)
level was at the lower limit of detectability The thiazide diuretic
wasdiscontinued, and the plasma calcium fell to 10.2 mg/100 ml.
Thiazides were started again, and several weeks later the plasma
calcium had risen again to 11.9 mg/100 ml. Progress over the next
several months is shown in Figure2; all the plasma calcium values
in this and subsequent figures are corrected for protein,^ Although
the hypercalcemia was evidently precipitated in part by thiazides,
the need to maintain effective suppression of urinary calcium
excretion was critical. Consequently, the thiazide was continued
and a trial of corticosteroids was begun, indicated also because of
persistently abnormal ventilatory function tests. Allopurinol was
given for hyperuricemia, a drug which may also be helpful in the
control of calcium nephrolithiasis." The initial dose of prednisone
was 60 mg daily then reduced to 30 mg, but the hypercalcemia
persisted. Although hydrocortisone has occasionally been more
effective than prednisone in the hypercalcemia of sarcoidosis,' it
did not prove so in this case. Only when the thiazide diuretic was
discontinued did the hypercalcemia show some response to the
corticosteroid treatment. Note that the period of refractory hypercalcemia occurred during the summer months, a point which will
be taken up later.

The patient was first seen at Henry Ford Hospital six months after
leaving Houston in November, 1975. There was no abnormality on
physical examination apart from the abdominal scars. In particular,
there was no enlargement of liver, spleen or lymph nodes, no
ocular calcification, and the blood pressure was normal. The
plasma calcium was higher (10.5 m g / d l ) and the urinary calcium
lower (162 m g / 2 4 hours) than previously, most likely a resultof the
thiazide diuretic therapy. The plasma creatinine was 1.9 m g / d l and
creatinine clearance only 50 ml/minute. The chest x-ray showed
persistent pulmonary infiltration which had notchanged duringthe
previous year. X-ray ofthe renal tract showed several small stones
on the left and a single large stone on the right, which had
progressively increased in size, although the projections were not
precisely comparable (Figure 1). The recurrence of stones after the
surgery in 1975 could have been due to the administration of
supplemental phosphate to a patient with recurrent urinary tract
infection, but the stones continued to grow even after the phosphate supplement had been discontinued. Despite worsen ing renal
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Fig.1
Serial plain films of renal tract over one-year period showing increase in
size of stone and decrease in size of kidney.
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Fig. 2
Serial values for plasma calcium. Bendroflumethiazide worsened hypercalcemia and blocked the response to corticosteroid; normocalcemia was
not restored even after the thiazide was discontinued. Note that the
progressive rise in plasma calcium occurred during the summer. All values
for total calcium inthis and subsequent figures are corrected for protein.'

8/30/77

Fig. 3
Serial values for plasma calcium and inorganic phosphate while in
hospital. There was a rapid fall in both total and ionized calcium, but mild
hypercalcemia persisted. The combination of lasix and sodium chloride
produced no further significant change.

Despite the low PTH level, hypercalcemia refractory to corticosteroids in a patient with sarcoidosis suggested co-existing primary
hyperparathyroidism, and in November, 1976 the patient was
admitted to the hospital for further study. Other possible causes of
hypercalcemia were ruled out by appropriate tests. Looking for
further evidence of possible hyperparathyroidism, a bone biopsy
was performed which showed an increase in the proportion ofthe
trabecular surface covered by osteoclasts. Although this was
consistent with hyperparathyroidism, other features of the bone
biopsy were against this diagnosis. The bone mineral content ofthe
radius measured by photon absorptiometry was normal. While
these studies were proceeding, the dietary intake of calcium was
further reduced to 150 mg/day, and the plasma calcium fell slowly
to 10.1 mg/100 ml, a normal value. The ionized calcium was only
marginally raised at 4.7 mg/100 ml (4.6 being the upper limit of
normal).

tubular responsiveness to PTH,'^ was zero. The patient reluctantly
agreed to the reinstitution of prednisone, which produced a rapid
fall in plasma calcium to nearly normal (Figure 3). Two hundred
mEq of sodium chloride combined with furosemide 80 mg daily
was then given in the hope that increasing the urinary excretion of
sodium would also increase urinary calcium excretion and further
lower the plasma calcium. There was no further change in total
calcium although there was a suggestive fall in ionized calcium.
The possibility of a pituitary or hypothalamic cause for amenorrhea
was reconsidered despite the previously negative investigations,
because galactorrhea was detected for the first time. Since sarcoid
granulomas can occur in the central nervous system, the amenorrhea could havebeen thefirst symptom of thedisease. Thyroid and
adrenal function were again normal. The plasma prolactin level
was 720 n g / m l , which was very high, and both the LH and ESH
levels were abnormally low. Laminograms of the pituitary fossa
indicated the presence of a tumor which was removed on February
20,1978 bytrans-sphenoidal hypophysectomy; the plasma prolactin fell to 44.6 n g / m l . The excess prolactin may have accounted for
some ofthe unusual aspects of the disordered calcium metabolism
as well as for amenorrhoea and galactorrhea.

Rigorous dietary calcium restriction and prednisone 30 mg on
alternate days were continued at home. Plasma calcium remained
normal for the next six months; in May, 1977 it was 9.8 mg/100 ml
and the serum creatinine had fallen to 1.3. The patient was
concerned about her Cushingoid facies and a weight gain of 26
pounds. For this reason and also because there had been no
improvement either in the chest x-ray or in ventilatory function
tests, prednisone was gradually withdrawn. This was quickly
followed by a recurrence of severe hypercalcemia requiring
hospital admission. As in the previous year this episode occurred
during the summer months. The creatinine clearance had fallen to
24 ml/minute, the tubular reabsorption of phosphate was decreased, and the tubular reabsorption of calcium was increased
(Table 1), Although both of these findings are consistent with
increased PTH secretion, the PTH measured by radio-immunoassay was undetectable and the nephrogenous cyclic adenosine
monophosphate (Nc'AMP) excretion, a more specific test of renal

Discussion
This patient has sarcoidosis, hypercalciuria, nephrolithiasis,
and hypercalcemia exacerbated by thiazides but responding eventually to corticosteroids, associated with a prolactin
secreting pituitary tumor. Three aspects ofthe case will be
discussed; first, the various diagnostic procedures which
indicated that the patient did not have hyperparathyroidism
as well as sarcoidosis; second, the pathophysiology of the
calcium disturbances in sarcoidosis and in thiazide diuretic
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therapy and their possible relationship to prolactin; and
third, the difficult problems in treating this patient.

at least three separate immunogenic sites along the PTH
molecule, and different antisera may react with any combination of these. The PTH molecule is broken up into
shorter fragments both in the liver and in the kidney. The
majorcomponent of immuno-assayable PTH in the circulation is a C terminal fragment (molecularweight about 7,000
daltons) which has a long half-life and is biologically inert.
Cleavage at a different site may also produce a biologically
active fragment and a shorter inactive fragment. Because of
these complexities no one really knows what they are
measuring by a particular radio-immunoassay. Fortunately,
the interpretation ofa negative result is more certain. In this
patient the PTH level was low or undetectable with four
different assays in four different laboratories at various times.

Differentiation between sarcoidosis with hypercalcemia
and hyperparathyroidism
There is no doubt that the patient had sarcoidosis, but in this
disease there is an increased prevalence of primary hyperparathyroidism.'This rarely causes rapidly changing hypercalcemia,* but in patients w i t h both diseases the
hypercalcemia does not respond to corticosteroids, so that
exclusion of primary hyperparathyroidism was of particular
importance in this patienL Figure 4 shows the effect of a
standard cortisone test, 150 mg daily for 10 days, in three
patients, one w i t h primary hyperparathyroidism w h o
showed no change in plasma calcium, one with sarcoidosis
showing a fall in plasma calcium to normal, and one with
both diseases in whom the effect was the same as in primary
hyperparathyroidism alone. As a general rule, when a
patient has both primary hyperparathyroidism and some
other disease which can cause hypercalcemia, the hypercalcemia is due entirely to the hyperparathyroidism. Only
very rarely does the second disease make an independent
contribution.

PTH reduces the tubular reabsorption of phosphate, and
tests based on this action have been used in diagnosis forthe
last 20 years. From simultaneous measurements of the
concentrations of phosphate and creatinine in plasma and
urine it is possible to calculate the percentage ofthe filtered
load of phosphate which is reabsorbed, ft is physiologically
more accurate to use the same data to calculate the mean
threshold of phosphate excretion, which is numerically
equal to the maximum reabsorptive capacity corrected for
glomerular filtration rate or TmP/GFR.' This quantity is
almost always low in hyperparathyroidism, but there are
many other influences on phosphate excretion so that the
test is nonspecific. Low values can occur with any form of
hypercalcemia, as in the present case.

Although the obvious way of excluding overactivity of an
endocrine gland is to measure the relevant hormone in the
blood, this is much more complex for PTH than for almost
any other hormone. PTH is an 84-amino-acid polypeptide
with biologic activity residing in the first 34 amino-acids at
the amino terminus. Like other peptide hormones, PTH is
measured by radio-immunoassay; in the absence of pure
human hormone, antibodies are raised by immunizing
animals with bovine PTH, which resembles the human
hormone sufficiently for antibodies to crossreact. There are
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PTH also increases the tubular reabsorption of calcium,
which is best shown by relating urinary calcium excretion/100 ml of creatinine clearance to the simultaneously
measured plasma calcium. In primary hyperparathyroidism
the urinary calcium is less than would be expected for the
same degree of hypercalcemia produced by calcium infusion, indicating increased tubular reabsorption.^"Thistest is
nonspecific because the tubular reabsorption of calcium, as
of phosphate, is infiueneed by many otherfactors. One in
particular is sodium balance. Sodium depletion and contraction of the extracellular fluid volume lead to increased
tubular reabsorption of sodium and also of calcium. Patients
with severe hypercalcemia of whatever etiology are frequently dehydrated because of vomiting and polyuria so
that salt depletion and increased tubular reabsorption of
calcium are to be expected. Forthis reason, correcfion of salt
depletion is an important component of the treatment of
severe hypercalcemia.^The tubular reabsorption of calcium
in this patient when assessed in this manner was normal
when she was first seen, and increased during the second
episode of severe hypercalcemia, but this increase was the
result of dehydration, notof increased PTH secretion.

Alone

10 12 14

DAYS

Fig. 4
Response of plasma calcium and inorganic phosphate and 24-hour urinary
calcium to standard cortisone test. Note the fall of plasma calcium to
normal in sarcoidosis alone, and no significant change in primary
hyperparathyroidism w i t h or without sarcoidosis.

Another test based on the action of PTH on the renal tubule
is the excretion of c y c l i c adenosine monophosphate
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(c'AMP). PTH, like many other peptide hormones, initiates
its biologic effects by binding to a receptor at the cell
membrane. This leadsto activation ofthe membrane-bound
enzyme adenylate cyclase which catalyzes the conversion
of ATP to c'AMP. Inthe renal tubule cell this action occurs at
the base or antiluminal pole. Some ofthe c'AMPenters the
cell and travels to the luminal pole where it leads to
inhibition ofthe entry of phosphate from the tubular lumen.
The c'AMP then passes out ofthe cell into the lumen and is
eventually excreted in the urine. The urinary excretion of
c'AMP is also derived from two other sources unrelated to
the action of PTH. First, c'AMP is produced in many tissues
by the action of catecholamines, glucagon and other hormones, and the surplus c'AMP is excreted in the urine.
Second, antidiuretic hormone also acts on the renal tubule
by activating adenylate cyclase. By measuring the plasma
level of c'AMP and the creatinine clearance, the filtered load
of c'AMP can be determined and subtracted from the total
urinary excretion to give the nephrogenous componenL In
order to suppress A D H secretion, water diuresis is induced
so that the nephrogenous c'AMP is then a reflection solely of
endogenous PTH secretion, A further refinement is to express nephrogenous c'AMP excretion/100 ml creatinine
clearance. This is a measure of the tubular response to PTH
per unit of functioning renal tissue and can be used to assess
parathyroid function in renal failure. Nephrogenous c'AMP
Is somewhat less sensitive than tests based on the tubular
reabsorption of phosphate or of calcium, in that normal
values occur more commonly in patients with proven
hyperparathyroidism. But ft is more precise in that elevated
values more certainly indicate hyperparathyroidism and
abnormally low values more certainly indicate its absence.
In this patient the nephrogenous c'AMP was undetectable.

where osteoclastic resorption was increased, and the iliac
cortex where there were no osteoclasts at all. Like the
change in tubular reabsorption of calcium and phosphate,
an increase in the extent of surface resorption is not specific
for hyperparathyroidism but occurs in several other conditions causing hypercalcemia, including vitamin D poisoning and sarcoidosis.
TABLE I
Diagnostic Information For and Against Concomitant
Hyperparathyroidism (HPT)

History
TmP/GFR (mg/100 ml)
Tubular reabsorption
of Ca'
Response to
thiazides (TZ)
Bone mineral content
Response to
corticosteroids
(on TZ)
Response to
corticosteroids
(off TZ)
Nephrogenous c'AMP
PTH

For HPT
nephrolithiasis

Against HPT
initial
normocalcemia

2.2 (NR 2,8-4,2)
increased
plasma Ga rose
normal

no change

plasma Ca fell
zero
undetectable

' Based on relationship between calcium excretion (0,61 mg/100 ml
Ccr) and plasma calcium (14,2 mg/100 ml) in comparison with
normal values.'"

A final point concerning the state of the bones is the
measurement of the bone mineral content ofthe radius by
photon absorptiometry. The scans are made with the Norland-Cameron instrument across the forearm at two sites: a
proximal site about one-third ofthe distance from the styloid
process to the olecranon, where the bone is almost entirely
cortical; and a more distal site about one-tenth of the
distance from the olecranon, where there is a higher proportion of trabecular bone. In hyperparathyroidism the values
tend to be reduced at both sites, but there is a relatively
greater reduction at the distal site. In our patient both values
and the relationship between them were normal.

Patients with hyperparathyroidism may have changes in the
bones, usually characterized by an increase in the proportion of bone surface undergoing both resorption and formation. Bone resorption is indicated microscopically by the
presence of scalloped erosions ofthe bone surface known as
Howship's lacunae. If these contain osteoclasts, which are
large multinucleated cells, it is reasonable to infer that
resorption was active at the time ofthe biopsy, but frequently
Howship's lacunae contain other kinds of cell or no cells at
all, indicating that resorption was probably not active.
Normally, Howship's lacunae occupy about 5% of the total
trabecular bone surface, but only about 10% o f t h e Howship's lacunar surface is lined by osteoclasts. In the present
case (Table I), there was a substantial increase in both the
total resorption surface and the active or osteoclast-lined
resorption surface, but a paradoxical decrease in the extent
of the bone forming surface, in contrast to the increase
usually observed in hyperparathyroidism. There was also a
marked discrepancy between the iliac trabecular surface

The rapid response ofthe hypercalcemia to corticosteroids
on the second occasion when the patient was not taking
thiazide diuretics is very strong evidence against hyperparathyroidism. Typical responses to steroids are shown in
Figure 4. Although steroid responsive hypercalcemia has
been recorded in a few patients w i t h primary hyperparathyroidism, they all had a more rapidly progressive form
ofthe disease than usual, characterized by a short history,
large tumors, and frequent presence of osteitis fibrosa.
Slowly progressive hyperparathyroidism without overt
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bone disease is never responsive to corticosteroids.^

daily, or exposure ofthe skin to ultraviolet light may induce
hypercalcemia,^ although these procedures have no effect
in a normal person. This abnormal sensitivity explains the
spontaneous disappearance of hypercalcemia which may
follow hospital admission^ as well as the seasonal variation
in the intensity ofthe calcium disorder. In a study at Duke
University some years ago,"all plasmacalcium estimations
in patients with sarcoidosis for a whole year were exam ined.
They showed a significant increase during the summer
months, whereas all the other values accumulated during
the same period showed no change. In our patient, a
seasonal fluctuation was clearly evident, and in retrospect, it
was a mistake to withdraw corticosteroids at the beginning
ofthe summer.

Table II summarizes the results ofthe various diagnostic tests
and their bearing on the presence or absence of concomitant
hyperparathyroidism in this patienL Although exacerbation
of hypercalcemia with thiazides is characterisfic of primary
hyperparathyroidism, it may also occur in other cond itions.
Each of the other test results tending to favor the d iagnosis of
hyperparathyroidism is nonspecific and susceptible of alternative interpretations. On the other hand, the combination
of undetectable PTH, zero nephrogenous cyclic AMP, and
suppression of hypercalcemia by prednisone is conclusive
evidence against hyperparathyroidism.
TABLE II
Measurements on Iliac Bone Biopsy After
Double Tetracycline Labelling
Normal
Range

Present

Total bone volume (%TMT)*
Total formation surtace (%TS)*'
Osteoblast surface (%TS)
Total resorption surface (%TS)
Gsteoclast surface (%TS)
Gsteold seam width (um)

20,2 ±4,0
12,9 ±5.8
5.0 ±3.3
5.8 + 2,0
1.0 ±0,5
12.0 ±3,4

12.1
2.2
1.6
29.2
6.-3
6.7

Appositional rate(um/d)

0.75 ±0.12

0.4

Quantity

Anotherconsequence ofthe increased sensitivity to sunlight
isthe pronounced geographic variation inthe prevalence of
the calcium disorder. In Washington DC, where summer is
short and many patients are dark skinned, hypercalcemia is
rare and occurs only in patients with extensive and severe
disease.^* By contrast, in Queensland, Australia, with a
predominantly light-skinned population exposed to tropical
sunlight forthe entire year, hypercalciuria is almost universal and hypercalcemia occurs in 30% of patients. This is so
even in asymptomatic persons whose only manifestation of
the disease is enlarged hilar lymph nodes discovered by
compulsory annual chest x-ray.

Case

* TMT = total marrow tissue
**TS = total surface

The precise nature of the disorder of vitamin D metabolism
in sarcoidosis remains to be d e t e r m i n e d . T h e plasma level
of 25HCC is normal and rises to the sameextent as in normal
subjects in response to vitamin D administration or to
ultraviolet irradiation ofthe skin; thus, there is no increase in
the conversion of vitamin D to its first metabolite in the liver.
Plasma levels of 1,25DHCC have been measured only in a
few patients, and values to date have been either normal or
only marginally raised. Since the calcium hyperabsorption
of sarcoidosis leads to suppression of PTH, and since PTH is
one of the factors w h i c h stimulates the f o r m a t i o n of
1,25DHCC by the kidney, the plasma levels of this metabolite should be low. A normal value, therefore, may reflect
a failure to suppress the process of renal 1-hydroxylation.
However, the levels in the blood are lowerthan are found in
idiopathic hypercalciuria, in which increased intestinal
absorption of calcium is accompanied by a normal plasma
c a l c i u m . f t is therefore unlikely thatthe hypercalcemia of
sarcoidosis can be attributed solely to increased production
of 1,25DHCC. Finally, when patients with sarcoidosis are
given 1,25DHCC they show the same increase in intestinal
absorption and urinary excretion of calcium as normal
persons. The increased sensitivity to vitamin D in sarcoidosis cannot be explained within the framework of
current knowledge of vitamin D metabolism, which suggests that another, as yet unidentified, metabolite of vitamin

The calcium disorder in sarcoidosis and its relationship to
hyperprolactinemia and thiazide diuretic administration
In sarcoidosis the metabolic state resembles closely that of
vitamin D intoxication. There is increased gastrointestinal
absorption of calcium, increased bone turnover, hypercalciuria, and hypercalcemia, all o f w h i c h are reversed by
the administration of corticosteroids, just as in vitamin D
poisoning.^ Even in patients whose calcium metabolism
appears to be normal there may be increased urinary
hydroxyproline excretion and suppressed PTH levels, so
that the calcium disorder probably affects all patients with
the disease, although the intensity varies considerably from
one patient to another."'^^ Vitamin D (or cholecalciferol),
whether ingested as such in the diet or synthesized in the
skin in response to irradiation by ultraviolet light, is biologically inactive. It is converted in the liver to 25-hydroxycholecalciferol (25HCC), which in turn is converted in the
kidneyeither to 1,25-dihydroxycholecalciferol (1,25DHCC)
or to 2 4 , 2 5 - d i h y d r o x y c h o l e c a l c i f e r o l ( 2 4 , 2 5 D H C C ) .
25HCC is active in high dose, but 1,25DHCC is much more
potent and is the main physiologically active metabolite.
Patients with sarcoidosis are abnormally sensitive to vitamin
D, in that small oral doses, such as 0.25 mg or 10,000 units
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D may be produced in excessive amounts in this disease.

that the chloroquine was given coincidentally at the time of
a spontaneous remission. If refractory hypercalcemia recurs
in the summer despite a return of the plasma prolactin level
to normal, chloroquine might be used in this patient.

In some experimental animals prolactin is a potent stimulus
to the formation of 1,25DHCC,'' which may explain the
increased intestinal absorption of calcium that occurs during lactation. Enhancement by prolactin ofthe synthesis of
1,25DHCC is an attractive explanation for the unusual
refractoriness to treatment in this patient, but plasma levels
of 1,25DHCC are not yet available. If this explanation is
correct, her hypercalcemia should be much less of a
problem during future summers.
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The undoubted relationship between hypercalcemia and
thiazide diuretic administration in this patient is noteworthy.
In normal subjects thiazides reduce the urinary excretion of
calcium but plasma calcium corrected for protein does not
change,^" In primary hyperparathyroidism thiazides characteristically cause further elevation ofthe plasma calcium but
may have the same effect in patients receiving high doses of
vitamin D either for osteoporosis^' or for hypoparathyroidism.^" It is therefore not surprising that thiazide-induced
hypercalcemia should also occur in sarcoidosis; evidently,
precipitation of hypercalcemia by thiazide diuretics does
not necessarily indicate hyperparathyroidism.
Treatment of the calcium disturbance in sarcoidosis
In patients w i t h h y p e r c a l c i u r i a alone urinary c a l c i u m
should be reduced if possible in orderto minimize the risk of
nephrolithiasis. Thiazide diuretics are effective and may
lower urinary calcium without raising plasma calcium, as in
hypercalciuria from other causes. It is not known why
hypercalcemia occurs in some patients but not in others.
Corticosteroids are unsatisfactory because any beneficial
effect due to reversal of the abnormality caused by the
disease may be nullified by the direct hypercalciuric effect
ofthe medication itself. Cellulose phosphate binds calcium
and magnesium in the gut and is a useful adjunct to a low
calcium diet,^^ but unfortunately it is not yet available in the
United States.
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